Skip to main content
Springer logoLink to Springer
. 2016 Feb 19;33(3):357–368. doi: 10.1007/s12325-016-0298-5

Cervical Lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: A Collective International Review

Henrik Hellquist 1, Alena Skálová 2, Leon Barnes 3, Antonio Cardesa 4, Lester D R Thompson 5, Asterios Triantafyllou 6, Michelle D Williams 7, Kenneth O Devaney 8, Douglas R Gnepp 9,10, Justin A Bishop 11, Bruce M Wenig 12, Carlos Suárez 14,15, Juan P Rodrigo 13,15, Andrés Coca-Pelaz 13, Primož Strojan 16, Jatin P Shah 17, Marc Hamoir 18, Patrick J Bradley 19,20, Carl E Silver 21, Pieter J Slootweg 22, Vincent Vander Poorten 20,23, Afshin Teymoortash 24, Jesus E Medina 25, K Thomas Robbins 26, Karen T Pitman 27, Luiz P Kowalski 28, Remco de Bree 29, William M Mendenhall 30, Jean Anderson Eloy 31, Robert P Takes 32, Alessandra Rinaldo 33, Alfio Ferlito 34,
PMCID: PMC4833802  PMID: 26895332

Abstract

Adenoid cystic carcinoma (AdCC) is among the most common malignant tumors of the salivary glands. It is characterized by a prolonged clinical course, with frequent local recurrences, late onset of metastases and fatal outcome. High-grade transformation (HGT) is an uncommon phenomenon among salivary carcinomas and is associated with increased tumor aggressiveness. In AdCC with high-grade transformation (AdCC–HGT), the clinical course deviates from the natural history of AdCC. It tends to be accelerated, with a high propensity for lymph node metastasis. In order to shed light on this rare event and, in particular, on treatment implications, we undertook this review: searching for all published cases of AdCC-HGT. We conclude that it is mandatory to perform elective neck dissection in patients with AdCC-HGT, due to the high risk of lymph node metastases associated with transformation.

Electronic supplementary material

The online version of this article (doi:10.1007/s12325-016-0298-5) contains supplementary material, which is available to authorized users.

Keywords: Adenoid cystic carcinoma, Dedifferentiation, Fatal outcome, Local recurrence, High-grade transformation, Lymphatic metastasis, Neck dissection, Neoplasm recurrence, Salivary glands

Review

The concept of high-grade transformation (previously also termed dedifferentiation) in neoplasms was introduced in 1971. Dahlin and Beabout [1] described a distinct entity in which a low grade chondrosarcoma was associated with a histologically high-grade sarcoma. High-grade transformation (HGT) in salivary gland tumors is rare but has been described not only in adenoid cystic carcinoma (AdCC) but in acinic cell carcinoma (AcCC) [27], polymorphous low-grade adenocarcinoma [810], epithelial-myoepithelial carcinoma [1114], low-grade mucoepidermoid carcinoma [15], myoepithelial carcinoma [16], hyalinizing clear cell carcinoma [17, 18], and mammary analogue secretory carcinoma (MASC) [19, 20]. The molecular genetic mechanisms responsible for these transformations remain largely unknown but a few genes have been documented in HGT of salivary gland neoplasms, such as P53 gene mutation and C-MYC amplification [2124]. HGT in salivary tumors of low-grade malignancy, such as AcCC, is associated with a higher local recurrence rate, a higher propensity for local lymph node metastasis and, a dramatic worsening of prognosis. For example, AcCC has the best prognosis of all salivary malignancies (10-year survival ~90%), but HGT in AcCC significantly reduces the mean survival of patients to 4.3 years [5, 25].

HGT in AdCC (AdCC-HGT) was first described in 1999 by Cheuk et al. [26] as "dedifferentiated adenoid cystic carcinoma" and since then more than 40 cases have been reported in the literature, most of them involving sinonasal and palatal minor glands and the submandibular glands [21, 23, 2642]. AdCC-HGT is histologically characterized by a residual component of conventional AdCC and another distinct anaplastic cell population showing loss of the biphasic ductal and myoepithelial differentiation seen in conventional AdCC. HGT in AdCC may be apparent at the time of primary excision of the tumor or may develop in a recurrence [26]. The two components may be separate, but transitional zones can be recognized. The presence of a transitional zone may help to distinguish AdCC-HGT from a hybrid tumor in which one of the two components is an AdCC. It may also be that many of the hybrid tumors [43] reported in the literature represent HGT in different salivary tumors. The distinction between the solid type of AdCC and AdCC-HGT should be emphasized. The histological criteria distinguishing between the two have been outlined in 2007 by Seethala et al. [33]. The solid type of AdCC is known to have the worst prognosis of the different histological subtypes of conventional AdCCs. Distant metastasis developed in 73% of major salivary gland solid type AdCC compared to 8% and 17% in cribriform and tubular types, respectively [44]. Most reports indicate that the prognosis for patients with AdCC-HGT is even worse than for those with a solid type of AdCC [24, 33, 36] and thus its recognition is important for the individual patient. The cells in the solid type of AdCC have small hyperchromatic nuclei and a basaloid appearance; the transformed cells in AdCC-HGT have larger and more pleomorphic, vesicular nuclei. The tubular-cribriform component of AdCC retains some of the myoepithelial immunoprofile. The conventional AdCC component in AdCC-HGT can have any mixture of growth patterns, with predominance of the cribriform and tubular patterns. The HGT component, which usually is either a poorly differentiated adenocarcinoma, or less often, an undifferentiated carcinoma, shows cells with large pleomorphic nuclei and a high mitotic rate (Fig. 1). The nuclei contain vesicular chromatin with conspicuous nucleoli. Necrosis (including comedonecrosis) is common as is a desmoplastic stroma and, tumoral calcification. Squamous areas and micropapillary growth are unique patterns seen exclusively in AdCC-HGT as compared to conventional AdCC [33]. There is an altered immunoprofile detected as a loss of the abluminal layer of myoepithelial cells [e.g. p63 and other myoepithelial/basal cell markers such as calponin, smooth muscle actin (SMA) and smooth muscle myosin heavy chain (SMMHC)], although there may be S-100 protein expression. Ki-67 (often more than 50%) and p53 labeling indices are often elevated while CD117 is generally lost. In some cases, cyclin D1 overexpression, as well as p53 abnormalities in association with Her-2/neu overexpression or loss of pRb expression, have all been detected in the AdCC-HGT component [21, 26, 30]. Studies by Seethala et al. [24] have shown C-MYC amplification in the process of HGT in AdCCs while other oncogenes, more frequently on chromosome 17q23, are also present, warranting further investigation. Recently, Costa et al. [45] studied 8 cases of AdCC-HGT and demonstrated that MYB/NFIB translocation is not necessarily an early event in or fundamental for the progression into AdCC-HGT.

Fig. 1.

Fig. 1

High-grade transformation in adenoid cystic carcinoma (AdCC-HGT). a The transformed AdCC consists of sheets of atypical, cells and loss of architecture usually seen in a conventional AdCC. b AdCC-HGT with a very high labeling index with Ki-67 (left) and a much more modest Ki-67 index in the remnants of the conventional AdCC (right)

There are statements that AdCC-HGT has a high propensity for lymph node metastasis, with as many as 57% of the patients showing metastatic disease compared to 5–25% of patients with conventional AdCC (cribriform, tubular and solid patterns) [33, 46]. The risk for nodal disease in AdCC-HGT is likely to be distinctly higher when compared to conventional AdCC as many lymph nodes in cases of conventional AdCC are involved by direct extension from the primary tumor rather by a true metastasis as identified in our review of 44 cases of AdCC-HGT reported in the literature (Table 1) [21, 23, 2642, 45, 47]. Kusafuka et al. [48] described a case of early transformation only and therefore was not included. Taking into account the possibility that some or even many of the reported hybrid tumors may represent HGT in different tumors, the number of AdCC-HGT could be even higher. Of the approximately 35 cases of hybrid tumors reviewed by Hellquist and Skalova [49], AdCC was the most common malignancy and was seen in 18 of the 33 malignant cases: two hybrid tumors comprised benign components only, and all but one of the remainder had two malignant components. The present review revealed cervical lymph node metastasis in 12 of 29 cases of AdCC-HGT. In 17 additional cases, the authors clearly stated there was no metastasis, while the remaining 15 reports did not include information about lymph node status. Thus, for the 29 cases in which information about lymph node metastasis (present or absent) was given, positive nodes were reported in 41% (12/29). In six cases with cervical lymph node metastasis distant metastases were also reported (50%). However synchronous or metachronous presentation could not be assessed in this review (Table 1). Seethala et al. [33] described 11 cases of AdCC-HGT where 4 of the 11 cases (36%) had cervical lymph node metastases with multiple positive nodes and extracapsular extension in all four cases (5 positive nodes of 29, 2/2, 3/18 and 2/22), a percentage similar to the literature review.

Table 1.

Review of reported cases of adenoid cystic carcinoma with high-grade transformation

Authors (year) [references] No. of cases Age Location Cervical lymph node metastasis Distant metastasis Remarks (gender, tumor size, status, follow-up)
Cheuk et al. (1999) [26] 3 55 Tongue Present Bone, lung F, NA, DOD, 15 months
53 Soft palate Absent Lung F, NA, DOD, 9 months
38 Hard palate Present Absent M, NA, DOD, 18 months
Moles et al. (1999) [27] 1 61 Tongue NA NA M, 3 cm, NED, 60 months
Terasaki et al. (2000) [28] 1 49 Lacrimal gland NA NA F, NA, NA, NA
Chau et al. (2001) [21] 1 64 L submandibular gland Present NA F, 3 cm, NED, 6 months
Ide et al. (2003) [29] 1 62 Soft palate NA NA M, 2.2 cm, NA, NA
Nagao et al. (2003) [30] 6 55 L maxillary sinus Present Bone, lung F, 6.0 cm, DOD, 6 months
51 R submandibular gland Absent Bone M, 4.5 cm, DOD, 24 months
35 L nasal cavity Absent Absent F, 1.8 cm, DOD, 36 months
70 R submandibular gland Present Absent M, 3.5 cm, DOD, 69 months
34 R maxillary sinus Present Absent F, NA, AWD, 60 months
36 L nasal cavity Absent Bone, lung M, 1.7 cm, DOD, NA
Brackrock et al. (2005) [31] 1 NA NA NA NA HGT first after radiotherapy
Sato et al. (2006) [32] 1 74 R maxillary sinus Absent Lung, liver, spleen, bone, pulmonaryhilar lymph nodes M, 4 cm, DOD, 4 months
Seethala et al. (2007) [33] 11 72 R maxillary sinus NA NA M, NA, NA, NA
59 Pterygopalatine Absent Absent M, NA, DOD, 12 months
57 R submandibular Present Lung M, 7 cm, DOD, 15 months
53 L nasal Absent Lung F, 4 cm, DOD, 12 months
62 R submandibular Present NA F, 1.7 cm, Alive, 48 months
61 R paranasal sinus NA NA F, NA, Dead, 44 months
66 R pyriform Absent NA M, 7 cm, Dead, 8 months
32 Maxillary Present NA M, 6 cm, NA, NA
64 R palate Absent NA F, 2.7 cm, AWD, 1 month
42 R submandibular Present Soft tissue M, 3 cm, AWD, 3 months
66 R submandibular Absent Absent M, 2 cm, Alive, 2 months
Handra-Luca et al. (2009) [34] 1 51 Maxillary sinus NA Lung F, NA, NA, NA
Malhotra et al. (2009) [35] 1 54 R parotid NA Absent M, 5 cm, NED, 5 months
Bonfitto et al. (2010) [23] 7 44 Submandibular Absent Absent F, T2, NA, 18 months
55 Palate Absent Absent F, T4, NED, 140 months
65 Paranasal sinus Absent Absent M, T4, Dead, 8 months
49 Parotid Absent Liver F, T3, Alive, 33 months
64 Submandibular Present Liver F, T2, DOD, 7 months
58 Lips Absent Absent F, T2, NED, 18 months
47 Palate Presenta Lung M, T4, Alive, 12 months
Costa et al. (2011)b [36] 1 61 Paranasal sinus NA Absent F, T2, Alive, 144 months
Panarelli et al. (2011) [37] 1 52 Lacrimal gland NA NA M, 3.2 cm, AWD, 12 months
Boland et al. (2012) [38] 3 61 Parotid NA NA F, NA, Alive, 169 months
56 Parotid NA NA M, NA, ANED, 77 months
40 Submandibular NA NA M, NA, ANED, 6 months
Argyris et al. (2013) [39] 1 39 Lacrimal gland NA NA F, 3 cm, AWD, 24 months
Bayle et al. (2013) [40] 1 45 Palate NA NA F, 4.5 cm, NA, NA
Ly et al. (2013) [41] 1 88 Parotid Absent Absent F, 3 cm, Alive, 12 months
Sayar et al. (2013) [42] 1 39 L submandibular gland Absent NA F, 4.0 cm, NED, 36 months
Total Data Available 44 54.4

2 Tongue

7 Palate

3 Lacrimal gland

11 Submandibular

9 Paranasal sinus

3 Nasal cavity

5 Parotid

3 Other

1 NA

17 Absent

12 Present

15 NA

13 Absent

13 Present

18 NA

Alive alive (no further information), ANED alive with no evidence of disease, AWD alive with disease, Dead dead (no further information), DOD dead of disease, F female, HGT high-grade transformation, L left, M male, NA information not available, NED no evidence of disease, No number, R right

aA later study by Costa et al. in 2012 [47] and another one in 2014 [45] comprised 8 cases; 7 of the cases derived from the 2010 study by Bonfitto et al. [23] and the additional 8th case from the 2011 study by Costa et al. [36]. In the 2014 study by Costa et al. [45], it is stated that this same particular palatal tumor did not have any cervical lymph node metastasis

bIn the 2011 study, Costa et al. [36] reported 6 cases of AdCC-HGT, however, 5 of the cases were included in the previous 2010 study by Bonfitto et al. [23]; hence only one new case presented in this 2011 study by Costa et al. [36]

In the study from the MD Anderson Cancer Center of 60 patients with early-stage (pT1, pT2) AdCC of conventional type, seven of the 30 patients who received neck dissection had occult metastasis (23%). This study primarily aimed to evaluate the risk for distant metastasis and survival rather than development of criteria for neck node dissection, but nevertheless, 43% of patients who had positive cervical lymph nodes after neck dissection developed distant metastasis compared to 17% who did not have positive nodes or a neck dissection. This study also demonstrated that 73% of patients with the solid subtype of conventional AdCC developed distant metastasis compared to 8% and 17% for cribriform and tubular subtypes, respectively. The subtype of AdCC among the seven patients who developed nodal disease was not specifically stated [44].

The concept of HGT in AdCC was widely accepted after the publication of Cheuk et al. [26] in 1999. There is, however, an uncertain number of reports of AdCC prior to that date, which today, according to the histological description, very likely would have been classified as AdCC-HGT. As an example, the 1985 report by Stillwagon et al. [50] would fit as AdCC-HGT: “Histologically, the tumor was an adenoid cystic carcinoma with cribriform and solid areas as well as some areas of undifferentiated carcinoma”. For obvious reasons, it is impossible to review all single case reports of AdCC in the literature to document possible cases of AdCC-HGT and, therefore, only cases classified as AdCC-HGT or dedifferentiated AdCC, published after 1999 have been included in this review and are summarized in Table 1. The current review of AdCC-HGT emphatically demonstrates the importance of a very generous sampling of the surgical specimens as the HGT component may be very small. In fact, ideally the entire tumor should be sectioned and examined whenever possible. Not only will careful dissection and histologic evaluation help to identify any possible focus of HGT, but may also highlight areas of solid subtype in a conventional AdCC.

Conclusion

Based on the literature review, lymph node metastasis may occur in 43–57% of patients with AdCC-HGT. This high propensity for lymph node metastases, which is at least 5–10 times higher than for conventional AdCC, strongly supports the use of neck dissection for patients with this unique histology. Preoperative staging workup is mandatory due to the high risk of distant metastasis. In situations where such histology is not recognized until after extirpative surgery for the primary, it appears justified to subsequently include the neck electively in the post-operative radiotherapy or perform a postoperative elective neck dissection (if distant metastasis are ruled out) followed by adjuvant radiation therapy to the primary site and the regional lymph nodes.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Disclosures

Henrik Hellquist, Alena Skálová, Leon Barnes, Antonio Cardesa, Lester D. R. Thompson, Asterios Triantafyllou, Michelle D. Williams, Kenneth O. Devaney, Douglas R. Gnepp, Justin A. Bishop, Bruce M. Wenig, Carlos Suárez, Juan P. Rodrigo, Andrés Coca-Pelaz, Primož Strojan, Jatin P. Shah, Marc Hamoir, Patrick J. Bradley, Carl E. Silver, Pieter J. Slootweg, Vincent Vander Poorten, Afshin Teymoortash, Jesus E. Medina, K. Thomas Robbins, Karen T. Pitman, Luiz P. Kowalski, Remco de Bree, William M. Mendenhall, Jean Anderson Eloy, Robert P. Takes, Alessandra Rinaldo and Alfio Ferlito have nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Footnotes

This article was written by members and invitees of the International Head and Neck Scientific Group (https://www.IHNSG.com).

References

  • 1.Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas. Cancer. 1971;28:461–466. doi: 10.1002/1097-0142(197108)28:2<461::AID-CNCR2820280227>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 2.Stanley RJ, Weiland LH, Olsen KD, Pearson BW. Dedifferentiated acinic cell (acinous) carcinoma of the parotid gland. Otolaryngol Head Neck Surg. 1988;98:155–161. doi: 10.1177/019459988809800210. [DOI] [PubMed] [Google Scholar]
  • 3.Henley JD, Geary WA, Jackson CL, Wu CD, Gnepp DR. Dedifferentiated acinic cell carcinoma of the parotid gland: a distinct rarely described entity. Hum Pathol. 1997;28:869–873. doi: 10.1016/S0046-8177(97)90164-7. [DOI] [PubMed] [Google Scholar]
  • 4.Di Palma S, Corletto V, Lavarino C, Birindelli S, Pilotti S. Unilateral aneuploid dedifferentiated acinic cell carcinoma associated with bilateral low grade diploid acinic cell carcinoma of the parotid gland. Virchows Arch. 1999;434:361–365. doi: 10.1007/s004280050353. [DOI] [PubMed] [Google Scholar]
  • 5.Skálová A, Sima R, Vanecek T, Muller S, Korabecna M, Nemcova J, Elmberger G, Leivo I, Passador-Santos F, Walter J, Rousarova M, Jedlickova K, Curik R, Geierova M, Michal M. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol. 2009;33:1137–1145. doi: 10.1097/PAS.0b013e3181a38e1c. [DOI] [PubMed] [Google Scholar]
  • 6.Ilayaraja V, Prasad H, Anuthama K, Sruthi R. Acinic cell carcinoma of minor salivary gland showing features of high-grade transformation. J Oral Maxillofac Pathol. 2014;18:97–101. doi: 10.4103/0973-029X.131925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Thompson LD, Aslam MN, Stall JN, Udager AM, Chiosea S, McHugh JB (2015) Clinicopathologic and immunophenotypic characterization of 25 cases of acinic cell carcinoma with high-grade transformation. Head Neck Pathol [Epub ahead of print]. [DOI] [PMC free article] [PubMed]
  • 8.Lloreta J, Serrano S, Corominas JM, Ferrés-Padró E. Polymorphous low-grade adenocarcinoma arising in the nasal cavities with an associated undifferentiated carcinoma. Ultrastruct Pathol. 1995;19:365–370. doi: 10.3109/01913129509021908. [DOI] [PubMed] [Google Scholar]
  • 9.Pelkey TJ, Mills SE. Histologic transformation of polymorphous low-grade adenocarcinoma of salivary gland. Am J Clin Pathol. 1999;111:785–791. doi: 10.1093/ajcp/111.6.785. [DOI] [PubMed] [Google Scholar]
  • 10.Simpson RH, Pereira EM, Ribeiro AC, Abdulkadir A, Reis-Filho JS. Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology. 2002;41:250–259. doi: 10.1046/j.1365-2559.2002.01439.x. [DOI] [PubMed] [Google Scholar]
  • 11.Alos L, Carrillo R, Ramos J, Baez JM, Mallofre C, Fernandez PL, Cardesa A. High-grade carcinoma component in epithelial-myoepithelial carcinoma of salivary glands clinicopathological, immunohistochemical and flow-cytometric study of three cases. Virchows Arch. 1999;434:291–299. doi: 10.1007/s004280050344. [DOI] [PubMed] [Google Scholar]
  • 12.Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol. 2007;31:44–57. doi: 10.1097/01.pas.0000213314.74423.d8. [DOI] [PubMed] [Google Scholar]
  • 13.Kusafuka K, Takizawa Y, Ueno T, Ishiki H, Asano R, Kamijo T, Iida Y, Ebihara M, Ota Y, Onitsuka T, Kameya T. Dedifferentiated epithelial-myoepithelial carcinoma of the parotid gland: a rare case report of immunohistochemical analysis and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:85–91. doi: 10.1016/j.tripleo.2008.01.013. [DOI] [PubMed] [Google Scholar]
  • 14.Roy P, Bullock MJ, Perez-Ordoñez B, Dardick I, Weinreb I. Epithelial-myoepithelial carcinoma with high grade transformation. Am J Surg Pathol. 2010;34:1258–1265. doi: 10.1097/PAS.0b013e3181e366d2. [DOI] [PubMed] [Google Scholar]
  • 15.Nagao T, Gaffey TA, Kay PA, Unni KK, Nascimento AG, Sebo TJ, Serizawa H, Minato H, Lewis JE. Dedifferentiation in low-grade mucoepidermoid carcinoma of the parotid gland. Hum Pathol. 2003;34:1068–1072. doi: 10.1053/S0046-8177(03)00418-0. [DOI] [PubMed] [Google Scholar]
  • 16.Ogawa I, Nishida T, Miyauchi M, Sato S, Takata T. Dedifferentiated malignant myoepithelioma of the parotid gland. Pathol Int. 2003;53:704–709. doi: 10.1046/j.1440-1827.2003.01536.x. [DOI] [PubMed] [Google Scholar]
  • 17.O’Regan E, Shandilya M, Gnepp DR, Timon C, Toner M. Hyalinizing clear cell carcinoma of salivary gland: an aggressive variant. Oral Oncol. 2004;40:348–352. doi: 10.1016/j.oraloncology.2003.08.023. [DOI] [PubMed] [Google Scholar]
  • 18.Jin R, Craddock KJ, Irish JC, Perez-Ordonez B, Weinreb I. Recurrent hyalinizing clear cell carcinoma of the base of tongue with high-grade transformation and EWSR1 gene rearrangement by FISH. Head Neck Pathol. 2012;6:389–394. doi: 10.1007/s12105-012-0338-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Skálová A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RHW, Hauer L, Andrle P, Hosticka L, Branžovský J, Michal M. Mammary analogue secretory carcinoma of salivary glands with high grade transformation: report of three cases with the ETV6-NTRK3 gene fusion and analysis of TP53, beta-catenin, EGFR and CCND1 genes. Am J Surg Pathol. 2014;38:23–33. doi: 10.1097/PAS.0000000000000088. [DOI] [PubMed] [Google Scholar]
  • 20.Luo W, Lindley SW, Lindley PH, Krempl GA, Seethala RR, Fung K-M. Mammary analog secretary carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of the literature. Int J Clin Exp Pathol. 2014;7:9008–9022. [PMC free article] [PubMed] [Google Scholar]
  • 21.Chau Y, Hongyo T, Aozasa K, Chan JK. Dedifferentiation of adenoid cystic carcinoma: report of a case implicating p53 gene mutation. Hum Pathol. 2001;32:1403–1407. doi: 10.1053/hupa.2001.28966. [DOI] [PubMed] [Google Scholar]
  • 22.Subramaniam MM, Ng SB, Seah SB, Anuar D, Soong R, Lee VK. Molecular characterization of dedifferentiated mucoepidermoid carcinoma of the trachea using laser microdissection-based TP53 mutation analysis. Histopathology. 2009;55:472–475. doi: 10.1111/j.1365-2559.2009.03385.x. [DOI] [PubMed] [Google Scholar]
  • 23.Bonfitto VL, Demasi AP, Costa AF, Bonfitto JF, Araujo VC, Altemani A. High-grade transformation of adenoid cystic carcinomas: a study of the expression of GLUT1 glucose transporter and of mitochondrial antigen. J Clin Pathol. 2010;63:615–619. doi: 10.1136/jcp.2010.075390. [DOI] [PubMed] [Google Scholar]
  • 24.Seethala RR, Cieply K, Barnes EL, Dacic S. Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch Pathol Lab Med. 2011;135:123–130. doi: 10.5858/2010-0048-OAR.1. [DOI] [PubMed] [Google Scholar]
  • 25.Hellquist H, Skálová A. Histopathology of the salivary glands. Heidelberg: Springer; 2014. High grade transformation in salivary gland neoplasms; pp. 432–434. [Google Scholar]
  • 26.Cheuk W, Chan JKC, Ngan RKC. Dedifferentiation in adenoid cystic carcinoma of salivary gland. An uncommon complication associated with an accelerated clinical course. Am J Surg Pathol. 1999;23:465–472. doi: 10.1097/00000478-199904000-00012. [DOI] [PubMed] [Google Scholar]
  • 27.Moles MA, Avila IR, Archila AR. Dedifferentiation occurring in adenoid cystic carcinoma of the tongue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:177–180. doi: 10.1016/S1079-2104(99)70114-9. [DOI] [PubMed] [Google Scholar]
  • 28.Terasaki M, Tokutomi T, Maruiwa H, Sugita Y, Harada H, Shigemori M. High-grade adenoid cystic carcinoma originating from the lacrimal gland. Brain Tumor Pathol. 2000;17:159–163. doi: 10.1007/BF02484288. [DOI] [PubMed] [Google Scholar]
  • 29.Ide F, Mishima K, Saito I. Small foci of high-grade carcinoma cells in adenoid cystic carcinoma represent an incipient phase of dedifferentiation. Histopathology. 2003;43:604–606. doi: 10.1111/j.1365-2559.2003.01682.x. [DOI] [PubMed] [Google Scholar]
  • 30.Nagao T, Gaffey TA, Serizawa H, Sugano I, Ishida Y, Yamazaki K, Tokashiki R, Yoshida T, Minato H, Kay PA, Lewis JE. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod Pathol. 2003;16:1265–1272. doi: 10.1097/01.MP.0000097366.88165.08. [DOI] [PubMed] [Google Scholar]
  • 31.Brackrock S, Krüll A, Röser K, Schwarz R, Riethdorf L, Alberti W. Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. Anticancer Res. 2005;25:1321–1326. [PubMed] [Google Scholar]
  • 32.Sato K, Ueda Y, Sakurai A, Ishikawa Y, Kaji S, Nojima T, Katsuda S. Adenoid cystic carcinoma of the maxillary sinus with gradual histologic transformation to high-grade adenocarcinoma: a comparative report with dedifferentiated carcinoma. Virchows Arch. 2006;448:204–208. doi: 10.1007/s00428-005-0054-8. [DOI] [PubMed] [Google Scholar]
  • 33.Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, Barnes EL. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol. 2007;31:1683–1694. doi: 10.1097/PAS.0b013e3180dc928c. [DOI] [PubMed] [Google Scholar]
  • 34.Handra-Luca A, Planchard D, Fouret P. Docetaxel-cisplatin-radiotherapy in adenoid cystic carcinoma with high-grade transformation. Oral Oncol. 2009;45:e208–e209. doi: 10.1016/j.oraloncology.2009.04.010. [DOI] [PubMed] [Google Scholar]
  • 35.Malhotra KP, Agrawal V, Pandey R. High grade transformation in adenoid cystic carcinoma of the parotid: report of a case with cytologic, histologic and immunohistochemical study. Head Neck Pathol. 2009;3:310–314. doi: 10.1007/s12105-009-0122-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Costa AF, Altemani A, Vékony H, Bloemena E, Fresno F, Suárez C, Llorente JL, Hermsen M. Genetic profile of adenoid cystic carcinomas (ACC) with high grade transformation versus solid type. Cell Oncol. 2011;34:369–379. doi: 10.1007/s13402-011-0037-5. [DOI] [PubMed] [Google Scholar]
  • 37.Panarelli JF, Zoumalan CI, Mukkamala K, Maher EA, Iacob C, Della Rocca DA. Dedifferentiated adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2011;27:e119–e121. doi: 10.1097/IOP.0b013e318201cb90. [DOI] [PubMed] [Google Scholar]
  • 38.Boland JM, McPhail ED, García JJ, Lewis JE, Schembri-Wismayer DJ. Detection of human papilloma virus and p16 expression in high-grade adenoid cystic carcinoma of the head and neck. Mod Pathol. 2012;25:529–536. doi: 10.1038/modpathol.2011.186. [DOI] [PubMed] [Google Scholar]
  • 39.Argyris PP, Pambuccian SE, Cayci Z, Singh C, Tosios KI, Koutlas IG. Lacrimal gland adenoid cystic carcinoma with high-grade transformation to myoepithelial carcinoma: report of a case and review of the literature. Head Neck Pathol. 2013;7:85–92. doi: 10.1007/s12105-012-0383-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bayle RM, D’Mello S, Makaria S, Hosthor SS. Dedifferentiation in adenoid cystic carcinoma. J Oral Maxillofac Pathol. 2013;17:474–477. doi: 10.4103/0973-029X.125225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ly CK, Cheng HM, Vermeulen T. High grade transformation in a case of adenoid cystic carcinoma associated with Epstein-Barr virus expression. Pathology. 2013;45:693–695. doi: 10.1097/PAT.0000000000000012. [DOI] [PubMed] [Google Scholar]
  • 42.Sayar H, Sarioğlu S, Bakaris S, Yildirim I, Öztarakçi High-grade transformation of adenoid cystic carcinoma delineated with a fibrous rim: a case report. Balkan Med J. 2013;30:333–336. doi: 10.5152/balkanmedj.2013.7220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Seifert G, Donath K. Hybrid tumours of salivary glands. Definition and classification of five rare cases. Eur J Cancer B Oral Oncol. 1996;32:251–259. doi: 10.1016/0964-1955(95)00059-3. [DOI] [PubMed] [Google Scholar]
  • 44.Bhayani MK, Yener M, El-Naggar A, Garden A, Hanna EY, Weber RS, Kupferman ME. Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. Cancer. 2012;118:2872–2878. doi: 10.1002/cncr.26549. [DOI] [PubMed] [Google Scholar]
  • 45.Costa AF, Altemani A, García-Inclán C, Fresno F, Suárez C, Llorente JL, Hermsen M. Analysis of MYB oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression. Lab Invest. 2014;94:692–702. doi: 10.1038/labinvest.2014.59. [DOI] [PubMed] [Google Scholar]
  • 46.Nagao T. “Dedifferentiation” and high-grade transformation in salivary gland carcinomas. Head Neck Pathol. 2013;7:37–47. doi: 10.1007/s12105-013-0458-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Costa AF, Tasso MG, Mariano FV, Soares AB, Chone CT, Crespo AN, Fresno MF, Llorente JL, Suárez C, de Araújo VC, Hermsen M, Altemani A. Levels and patterns of expression of hypoxia-inducible factor-1α, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation. Histopathology. 2012;60:816–825. doi: 10.1111/j.1365-2559.2011.04128.x. [DOI] [PubMed] [Google Scholar]
  • 48.Kusafuka K, Miki T, Nakajima T. Salivary adenoid cystic carcinoma with an early phase of high-grade transformation: case report with an immunohistochemical analysis. Diagn Pathol. 2013;8:113. doi: 10.1186/1746-1596-8-113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hellquist H, Skalova A. Histopathology of the salivary glands. Heidelberg: Springer; 2014. Hybrid tumour; pp. 415–418. [Google Scholar]
  • 50.Stillwagon GB, Smith RRL, Highstein C, Lee D-J. Adenoid cystic carcinoma of the supraglottic larynx: report of a case and review of the literature. Am J Otolaryngol. 1985;6:309–314. doi: 10.1016/S0196-0709(85)80060-0. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Advances in Therapy are provided here courtesy of Springer

RESOURCES